Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CF PharmTechHKSE:02652 +0.81%15 Market Cap is HK$6,370.8 Mil as of Aug. 11, 2026. GuruFocus rates HKSE:02652 with a GF Score™ of 15/100. The stock has 5 warning signs investors should review. Among 1,022 Drug Manufacturers companies, CF PharmTech ranks better than 69.18% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). CF PharmTech's share price for the quarter that ended in Dec. 2025 was HK$36. CF PharmTech's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 411.9 Mil. Therefore, CF PharmTech's market cap for the quarter that ended in Dec. 2025 was HK$14,828.8 Mil.
CF PharmTech's quarterly market cap
stayed the same
from Dec. 2023 (HK$0.0 Mil) to Dec. 2024 (HK$0.0 Mil) but then
increased
from Dec. 2024 (HK$0.0 Mil) to Dec. 2025 (HK$14,828.8 Mil).
CF PharmTech's annual market cap
stayed the same
from Dec. 2023 (HK$0.0 Mil) to Dec. 2024 (HK$0.0 Mil) but then
increased
from Dec. 2024 (HK$0.0 Mil) to Dec. 2025 (HK$14,828.8 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. CF PharmTech's Enterprise Value for Today is HK$5,780.9 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
CF PharmTech Market Cap Related Terms
CF PharmTech Market Cap Historical Data
* Premium members only.
The historical data trend for CF PharmTech's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CF PharmTech Market Cap Chart
CF PharmTech Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
Market Cap
0.00
0.00
0.00
14,828.80
CF PharmTech Semi-Annual Data
Dec22
Dec23
Dec24
Dec25
Market Cap
0.00
0.00
0.00
14,828.80
HKSE:02652 vs ZTS: Market Cap Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CF PharmTech's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CF PharmTech Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CF PharmTech's Market Cap distribution charts can be found below:
* The bar in red indicates where CF PharmTech's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
CF PharmTech's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CF PharmTech (HKSE:02652) has a Market Cap of HK$6,370.8 Mil as of Aug. 11, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on CF PharmTech and its competitors. According to the industry distribution chart, CF PharmTech ranks #315 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 30.8%.
Is CF PharmTech's Market Cap too high?
CF PharmTech's current Market Cap is HK$6,370.8 Mil. Based on the distribution chart, CF PharmTech ranks #315 out of 1022 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, CF PharmTech has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does CF PharmTech's Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CF PharmTech ranks #315 out of 1022 companies for Market Cap. This puts CF PharmTech in the upper half of its industry. The industry median Market Cap is 221.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 221.51, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on CF PharmTech and its competitors. For the Drug Manufacturers industry, the median Market Cap is 221.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CF PharmTech's current Market Cap is HK$6,370.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CF PharmTech stock overvalued right now?
CF PharmTech (HKSE:02652) has a current Market Cap of HK$6,370.8 Mil. The current Market Cap is HK$6,370.8 Mil. CF PharmTech's overall GF Score™ is 15/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For CF PharmTech (HKSE:02652), the current Market Cap is HK$6,370.8 Mil as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CF PharmTech Inc is engaged in inhalation drug delivery technology. It is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is a specialist in the development of complex inhalation formulations with high barriers to entry, and a platform-based pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, international regulatory filing, and commercialization. Leveraging its self-developed, globally integrated end-to-end capabilities, from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to small interfering RNA (siRNA) nucleic acid delivery platforms. Its therapeutic areas encompass respiratory diseases and nasal diseases.
15GF Score
Get the complete analysis for HKSE:02652
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02652 has been successfully added to your 
